Comparative Efficacy and Safety of Approved Therapies in ≥3L Relapsed/Refractory Large B-Cell Lymphoma: A Bayesian Network Meta-Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #ABCL-1491; Location: LEVEL 3, HALL B3; "Background: Multiple novel agents are approved for ≥3L relapsed/refractory large B-cell lymphoma, including chimeric antigen receptor T-cell (CAR-T) products (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisacel]), bispecific antibodies (epcoritamab, glofitamab, mosunetuzumab), antibody-drug conjugates (polatuzumab vedotin + bendamustine, rituximab [pola-BR], loncastuximab tesirine), and others (tafasitamab + lenalidomide, selinexor). CAR-T therapies ranked highest for CR rate but with greater toxicity and selection bias. Among bispecific antibodies, epcoritamab ranked among the most favorable for combined efficacy and safety (SUCRA, 58.3% vs 56.1% for glofitamab and 47.8% for mosunetuzumab). Given the near-disconnected, star-topology network and predominantly single-arm data, results carry very low certainty per CINeMA and should be interpreted cautiously."
Retrospective data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Nain Tara MD; Hina Zubair MD; Jiss Joy MD; Ayush Adhikari MD; Hamnah Tayyab MD; Giampaolo Talamo MD
|